Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease
Condition: Acquired Immune Deficiency SyndromeInterventions: Drug: Lopinavir 400 mg/ritonavir 100 mg; Drug: EfavirenzSponsors: Rush University Medical Center; Rush University Medical Center; University of Chicago; University of Illinois; Ruth M. Rothstein CORE Center; Abbott; Gilead SciencesTerminated - verified May 2013
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Highly Active Antiretroviral Therapy | Research